Antiplatelet for Coronary Artery Disease in Specific Condition "No Size Fits All"

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Antiplatelet agents are fundamental in managing coronary artery disease.
• Comorbidities significantly impact antiplatelet therapy efficacy and safety.
• Conditions like diabetes, aging, renal dysfunction, and atrial fibrillation alter platelet function and patient outcomes.

Purpose of the Study:

• To review platelet alterations in patients with common comorbidities.
• To examine current evidence on antiplatelet therapy in these patient groups.
• To provide recommendations for optimizing antiplatelet regimens.

Main Methods:

• Literature review of studies on antiplatelet therapy in patients with comorbidities.
• Analysis of platelet reactivity and response to antiplatelet agents.
• Evaluation of bleeding risk and therapeutic efficacy.

Main Results:

• Diabetes mellitus increases platelet reactivity and reduces antiplatelet response.
• Elderly patients exhibit diminished antiplatelet response and heightened bleeding risk.
• Renal dysfunction and atrial fibrillation (with anticoagulation) also compromise antiplatelet efficacy and increase bleeding.

Conclusions:

• Tailoring antiplatelet therapy is essential for patients with comorbidities.
• Optimizing antiplatelet selection minimizes adverse events while maximizing benefits.
• Further research and guideline adherence are recommended for improved patient care.